Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
Palbociclib is an oral CDK4/6 inhibitor indicated in HR+/HER2- advanced or metastatic breast cancer in combination with hormonotherapy. Its main toxicity is neutropenia. The aim of our study was to describe the kinetics of circulating neutrophils from real-life palbociclib-treated patients. A popula...
保存先:
| 主要な著者: | , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2021-10-01
|
| シリーズ: | Pharmaceutics |
| 主題: | |
| オンライン・アクセス: | https://www.mdpi.com/1999-4923/13/10/1708 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
